Bussone G, Boiardi A, Merati B, Recchia M, Salom Pedemonti D, Tansini E
Riv Patol Nerv Ment. 1981 Sep-Oct;101(5):247-53.
The therapeutic efficacy of tiapride in chronic headache (300 mg/day orally during 30 days) was studied in a doubleblind trial in a group of 50 patients, 40 of them with so-called "mixed headache", and 10 with classical migraine. The results were subjected to statistical analysis. 65% of treated patients had clinical benefit in the intensity and frequency of headaches. The mode of action of this drug is discussed, together with the involvement of several monoaminergic systems in the genesis of headache. The action of tiapride appears to be indirectly dopaminomimetic as it operates by a blockade of dopaminergic inhibitors receptors.
在一项双盲试验中，对50例患者（其中40例为所谓的“混合性头痛”，10例为典型偏头痛）研究了硫必利（每天口服300毫克，持续30天）对慢性头痛的治疗效果。对结果进行了统计分析。65%的接受治疗的患者在头痛强度和频率方面有临床获益。讨论了该药的作用方式，以及几种单胺能系统在头痛发生中的作用。硫必利的作用似乎是间接拟多巴胺能的，因为它通过阻断多巴胺能抑制受体起作用。
